Bristol Myers Squibb, BMS, Zolacabtagene Autoleucel, Zola-Cel, BMS-986353, Breakfree-2, Multiple Sclerosis, Progressive Multiple Sclerosis, Relapsing Multiple Sclerosis,

PRINCETON, N.J. — October 23, 2026 Bristol Myers Squibb (NYSE: BMY) announced interim safety and efficacy findings from the...